Stay updated with breaking news from Cassava Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AUSTIN, Texas, June 01, 2023 -- Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present... | June 1, 2023
The psychosis in Parkinson's and Alzheimer's disease market size shall grow during the forecast period (2023-2032). This increase will be due to rising disease awareness and improving diagnosis
/PRNewswire/ -- DelveInsight's Psychosis in Parkinson's and Alzheimer's Disease Market Insights report includes a comprehensive understanding of current...
If broadly covered, Leqembi, the new Alzheimer's drug from Biogen (BIIB) and Eisai (ESALF) (ESAIY), could add $2B - $5B costs to Medicare annually. Read more here.
Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) – Equities researchers at HC Wainwright issued their Q2 2023 EPS estimates for shares of Cassava Sciences in a research report issued to clients and investors on Tuesday, May 9th. HC Wainwright analyst V. Bernardino anticipates that the company will earn ($0.58) per share for the quarter. HC […]